MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
965.67%
Quick Ratio
965.67%
Cash Ratio
925.68%
Debt to Asset Ratio
10.67%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Prepaid expenses and other curre...
    • Other assets
    • Others
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Accrued expenses and other curre...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
171,593
189,163
213,192
133,265
Accounts receivable, net
0
0
18,000
-
Prepaid expenses and other current assets
7,413
6,400
5,463
1,298
Total current assets
179,006
195,563
236,655
134,563
Property and equipment, net
876
929
846
782
Operating lease right-of-use assets
1,271
1,372
1,469
1,564
Restricted cash
107
107
107
107
Other assets
1,498
1,159
1,216
1,253
Total assets
182,758
199,130
240,293
138,269
Accounts payable-Nonrelated Party
2,542
1,190
9,997
2,561
Accrued expenses and other current liabilities-Nonrelated Party
-
-
16,344
8,965
Accrued expenses and other current liabilities
7,407
4,433
-
-
Related party accounts payable and other current liabilities-Related Party
0
0
140
6,273
Deposit liability
5,000
5,000
5,000
-
Deferred revenue
3,117
3,117
4,156
-
Operating lease liability, current
471
453
435
417
Warrant liability, related party
-
-
0
2,088
Total current liabilities
18,537
14,193
36,072
20,304
Operating lease liability, noncurrent
966
1,090
1,209
1,324
Notes payable, noncurrent
-
-
0
0
Total liabilities
19,503
15,283
37,281
21,628
Series a non-voting convertible preferred shares, 0.001 par value 2,890 shares and no shares authorized as of december 31, 2025 and december 31, 2024, respectively 2,890 shares and no shares issued and outstanding as of december 31, 2025 and december 31, 2024, respectively-Series APreferred Stock
-
-
4,000
4,000
Non-voting convertible preferred shares, 0.001 par value 5,000,000 shares authorized as of june 30, 2026 and december 31, 2025 2,890 series a designated shares issued and outstanding as of june 30, 2026 and december 31, 2025
4,000
4,000
-
-
Ordinary shares, 0.001 par value 175,000,000 shares authorized as of june 30, 2026 and december 31, 2025, 27,756,044 and 27,556,767 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
28
28
28
14
Additional paid-in capital
379,156
374,911
370,793
192,039
Accumulated deficit
-219,929
-195,092
-171,809
-79,412
Total shareholders' equity
163,255
183,847
203,012
116,641
Total liabilities and shareholders equity
182,758
199,130
240,293
138,269
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$171,593K Prepaid expenses andother current assets$7,413K (368.58%↑ Y/Y)Total current assets$179,006K (16.07%↑ Y/Y)Other assets$1,498K (15.23%↑ Y/Y)Operating leaseright-of-use assets$1,271K (-20.91%↓ Y/Y)Property and equipment,net$876K (353.89%↑ Y/Y)Restricted cash$107K (0.94%↑ Y/Y)Total assets$182,758K (16.09%↑ Y/Y)Total liabilities andshareholders equity$182,758K (16.09%↑ Y/Y)Total shareholders'equity$163,255K (17.24%↑ Y/Y)Total liabilities$19,503K (7.28%↑ Y/Y)Accumulated deficit-$219,929K (-301.29%↓ Y/Y)Additional paid-in capital$379,156K (99.51%↑ Y/Y)Total currentliabilities$18,537K (10.70%↑ Y/Y)Operating leaseliability, noncurrent$966K (-32.59%↓ Y/Y)Non-voting convertiblepreferred shares, 0.001...$4,000K Ordinary shares, 0.001par value...$28K (100.00%↑ Y/Y)Accrued expenses andother current...$7,407K Deposit liability$5,000K Deferred revenue$3,117K Accountspayable-Nonrelated Party$2,542K (54.25%↑ Y/Y)Operating leaseliability, current$471K (123.22%↑ Y/Y)

CRESCENT BIOPHARMA, INC. (CBIO)

CRESCENT BIOPHARMA, INC. (CBIO)